These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24380960)

  • 41. Transitionality in addiction: A "temporal continuum" hypotheses involving the aberrant motivation, the hedonic dysregulation, and the aberrant learning.
    Patrono E; Gasbarri A; Tomaz C; Nishijo H
    Med Hypotheses; 2016 Aug; 93():62-70. PubMed ID: 27372858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Memory processes and addiction: involvement of the calcineurin signaling pathway].
    Biała G
    Postepy Hig Med Dosw (Online); 2007; 61():199-203. PubMed ID: 17507867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Psychotropic drugs in the management of alcoholism and drug addiction?].
    Athen D
    MMW Munch Med Wochenschr; 1982 Feb; 124(7):137-8. PubMed ID: 6801490
    [No Abstract]   [Full Text] [Related]  

  • 44. Drugs and addiction: an introduction to epigenetics.
    Wong CC; Mill J; Fernandes C
    Addiction; 2011 Mar; 106(3):480-9. PubMed ID: 21205049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.
    Licata SC; Renshaw PF
    Ann N Y Acad Sci; 2010 Feb; 1187():148-71. PubMed ID: 20201852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine D₁-D₂ receptor heteromer regulates signaling cascades involved in addiction: potential relevance to adolescent drug susceptibility.
    Perreault ML; O'Dowd BF; George SR
    Dev Neurosci; 2014; 36(3-4):287-96. PubMed ID: 24820626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From neurobiology to treatment: progress against addiction.
    Nestler EJ
    Nat Neurosci; 2002 Nov; 5 Suppl():1076-9. PubMed ID: 12403990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From Circuits to Chromatin: The Emerging Role of Epigenetics in Mental Health.
    Mews P; Calipari ES; Day J; Lobo MK; Bredy T; Abel T
    J Neurosci; 2021 Feb; 41(5):873-882. PubMed ID: 33446519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The addictive brain: all roads lead to dopamine.
    Blum K; Chen AL; Giordano J; Borsten J; Chen TJ; Hauser M; Simpatico T; Femino J; Braverman ER; Barh D
    J Psychoactive Drugs; 2012; 44(2):134-43. PubMed ID: 22880541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetics and addiction.
    Hamilton PJ; Nestler EJ
    Curr Opin Neurobiol; 2019 Dec; 59():128-136. PubMed ID: 31255844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-Abuse Nanotechnology: Opportunities and Challenges.
    Mahmoudi M; Pakpour S; Perry G
    ACS Chem Neurosci; 2018 Oct; 9(10):2288-2298. PubMed ID: 29851334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Focusing on the Opioid System for Addiction Biomarker Discovery.
    Belzeaux R; Lalanne L; Kieffer BL; Lutz PE
    Trends Mol Med; 2018 Feb; 24(2):206-220. PubMed ID: 29396147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of patients with substance use disorders, second edition. American Psychiatric Association.
    Kleber HD; Weiss RD; Anton RF; George TP; Greenfield SF; Kosten TR; O'Brien CP; Rounsaville BJ; Strain EC; Ziedonis DM; Hennessy G; Connery HS; McIntyre JS; Charles SC; Anzia DJ; Cook IA; Finnerty MT; Johnson BR; Nininger JE; Summergrad P; Woods SM; Yager J; Pyles R; Cross CD; Peele R; Shemo JP; Lurie L; Walker RD; Barnovitz MA; Gray SH; Saxena S; Tonnu T; Kunkle R; Albert AB; Fochtmann LJ; Hart C; Regier D; ; ;
    Am J Psychiatry; 2007 Apr; 164(4 Suppl):5-123. PubMed ID: 17569411
    [No Abstract]   [Full Text] [Related]  

  • 54. The role of oxytocin in alcohol and drug abuse.
    King CE; Gano A; Becker HC
    Brain Res; 2020 Jun; 1736():146761. PubMed ID: 32142721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroepigenetics and addiction.
    Walker DM; Nestler EJ
    Handb Clin Neurol; 2018; 148():747-765. PubMed ID: 29478612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurobehavioral Sequelae of Psychostimulant Abuse.
    Djamshidian A
    Int Rev Neurobiol; 2015; 120():161-77. PubMed ID: 26070757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medications development for food-based and drug use disorders.
    de Moura FB; Kohut SJ; Bergman J
    Adv Pharmacol; 2019; 86():197-236. PubMed ID: 31378252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BDNF During Withdrawal.
    Geoffroy H; Noble F
    Vitam Horm; 2017; 104():475-496. PubMed ID: 28215305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drugs of abuse: epigenetic mechanisms in toxicity and addiction.
    Kovatsi L; Fragou D; Samanidou V; Njau S; Kouidou S
    Curr Med Chem; 2011; 18(12):1765-74. PubMed ID: 21466474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment.
    Tsai SJ
    Med Hypotheses; 2007; 68(2):410-4. PubMed ID: 16824691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.